



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	108.24
Trade Time:	4:00 PM ET Dec 14, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	94.55 - 147.17
Volume	N/A

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Dec 11, 2017

[Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma](#)

Dec 10, 2017

[Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting](#)

Dec 7, 2017

[Long-Term Efficacy Data from the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated with ABRAXANE® Vs. Solvent-Based Paclitaxel to Be Reported](#)

Dec 5, 2017

[Celgene Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Capacity Building in Resource-Constrained Countries](#)

Nov 21, 2017

[Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American Society of Hematology Annual Meeting \(ASH\)](#)

## Financials [\[ View all \]](#)

Feb 10, 2017

[Annual Report \(10-K\)](#)

Apr 27, 2017

[Proxy Statement \(DEF 14A\)](#)

Oct 26, 2017

[Quarterly Report \(10-Q\)](#)

Jul 27, 2017

[Quarterly Report \(10-Q\)](#)

Apr 27, 2017

[Quarterly Report \(10-Q\)](#)

